Endogenex
2 known investors
Endogenex develops the pulsENDO system, an endoscopic medical device that applies pulsed electric field technology to the small intestine to reset metabolic signaling for people with type 2 diabetes. The company, founded in partnership with Mayo Clinic, is currently evaluating the investigational system in clinical trials.
HealthtechMedical Devices
Founders & leadership
BK
Barham K. Abu DayyehCo-inventor, pulsENDO system
Investors · 2
In the news
- Endogenex Closes $50 Million Series C Extension to Fund Pivotal Clinical Study and Path to FDA Approvalendogenex.com · 2026
- Endogenex Raises $50M To Advance ReCET Diabetes Trialhoodline.com · 2026
- Endogenex closes $50M Series C extension to support endoscopic diabetes proceduremassdevice.com · 2026
- Endogenex raises $50m to advance type 2 diabetes treatment - Medical Device Networkmedicaldevice-network.com · 2026
- Endogenex raises $50M for diabetes device clinical trials - Minneapolis / St. Paul Business Journalbizjournals.com · 2026
- Endogenex™ Announces $88 Million Series C Financing to Complete Pivotal Trial of the ReCET™ System in Patients with Type 2 Diabetesprnewswire.com · 2024